Asthma bronchiale is a common chronic inflammatory disease of the airways, causing increased secrection of mucus and narrowing airways. This results in frequent episodes of wheezing, breathlessness, coughing and chest tightness. Eosinophils, Neutrophils and Mast cells are some of the mediators involved in the inflammation. Several factors trigger asthma including genetic predisposition, environmental and immunologic factors. Atopic (extrinsic) asthma is caused by IgE - mediated reaction by binding to Mast cells and releasing mediators like histamine, chemokines and cytokines. Non-Atopic (intrinsic) asthma is elicit by non-immune stimuli like stress, exercise, aspirin, viruses, cold and inhaled irritants. Asthma can be classified according to severity (mild, moderate, severe) of the disease. Treatment is given according to the severity, and is divided into reliever and controller medication. Reliever medication is given for relieving symptoms like bronchoconstriction within few minutes. Salbutamol (SABA) and Ipratropium bromide (anticholinergic drug) are reliever drugs either used separately or together. ICS used together with LABA gives a long acting effect and are used as controller medication. LTRA, Theophylline and Cromolyn Sodium are also used. Omalizumab is used in anti-IgE therapy and is beneficial for severe allergic asthma. It is used as a long acting agent and shows a decrement in the recurrence and severity of asthma exacerbations. It has also reduced the amount of patients visiting the emergency departments by improving both FEV1 and morning PEF. Future treatments for asthma include several different humanized monoclonal antibodies which targets different sites in the inflammatory cascade. Also the use of herbal therapy has proven to be beneficial for asthma, but still needs more recognition and research. Patients should be provided with education and training from health care professionals, or from other helpful sources to use inhalers properly for most beneficial outcome.